Ocrelizumab Safe and Effective for Early-Stage Relapsing-Remitting MS
Ocrelizumab is safe and effective and provides long-term benefits for treatment-naïve patients with early-stage relapsing-remitting multiple sclerosis.
Stay updated with breaking news from Multiple Sclerosis Centers. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Ocrelizumab is safe and effective and provides long-term benefits for treatment-naïve patients with early-stage relapsing-remitting multiple sclerosis.
The impact of cognition on social roles and activities suggests the need of taking a closer look at cognitive impairment in patients with multiple sclerosis.
Long-term treatment of neuromyelitis optica spectrum disorder with satralizumab is safe and effective in reducing relapse risk in patients.
Icompanion may be a helpful tele-monitoring tool in encouraging more patient involvement and data-driven clinical decisions for multiple sclerosis care.
When treating pain in multiple sclerosis, a specialist is urging colleagues to think outside the box - especially since pain can evolve over time due to changes in MS and related conditions.